Skip to main content

Siemens Healthineers Invests $432M in Shanghai Diagnostics Plant

NEW YORK (360Dx) – Siemens Healthineers said recently that it has invested RMB 3 billion ($432.4 million) in a laboratory diagnostic plant in Shanghai, marking an important expansion to one of its key facilities in China.

The firm said that it already broke ground on the plant, which when finished will enable the manufacturing of imaging and laboratory diagnostics products. The Shanghai facility will become the first manufacturing location for Siemens Healthineers in the region that combines both in vivo and in vitro products.

Further, it will become the company’s first in vitro diagnostic reagent plant in the Asia Pacific region, producing clinical chemistry and immunoassay reagents.

The firm said that the new plant expands the company’s global manufacturing footprint and enhances its ability to better address the evolving needs of healthcare providers in China by enabling it to glean market insights and deliver local products. 

Michael Reitermann, member of the managing board and president of diagnostics of Siemens Healthineers, said in a statement that the investment in the new facility "underscores our long-term commitment to the growing healthcare market in the country and across the Asia Pacific region.”

The firm said it anticipates that the facility will deliver products that will support the advancement of the Healthy China 2030 plan, in which China’s political leaders have committed to making health a national priority.

Siemens anticipates that the new factory will create about 500 new jobs at full capacity.

Separately, Siemens Healthineers and Healthy.io said today that they have entered a global original equipment manufacturer (OEM) alliance to market a smartphone system for chronic kidney disease monitoring in the home.